(Reuters) - Tonix Pharmaceuticals Holding Corp said on Tuesday its experimental drug failed to meet the primary goal in a mid-stage study for management of widespread muscle pain and tenderness associated with long COVID-19.
Shares of the company were down 12% in premarket trading.
The...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.